Efficacy of pre-operative chemotherapy with docetaxel, cisplatin, and S-1 (DCS therapy) and curative resection for gastric cancer with pathologically positive para-aortic lymph nodes

Journal of Surgical Oncology

Volumn 105, Issue 6, 2012, Pages 535-541

  Oyama, Katsunobu ^a   Fushida, Sachio ^a   Kinoshita, Jun ^a   Makino, Isamu ^a   Nakamura, Keishi ^a   Hayashi, Hironori ^a   Nakagawara, Hisatoshi ^a   Tajima, Hidehiro ^a   Fujita, Hideto ^a   Takamura, Hiroyuki ^a   Ninomiya, Itasu ^a   Kitagawa, Hirohisa ^a   Tani, Takashi ^a   Fujimura, Takashi ^a   Ohta, Tetsuo ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

gastric cancer; para aortic lymph node dissection; para aortic lymph node metastasis; pre operative chemotherapy

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LYMPH NODE DISSECTION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; STOMACH CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DRUG COMBINATIONS; FEMALE; GASTRECTOMY; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; OXONIC ACID; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS; TEGAFUR;

EID: 84859724627     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22125     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics. 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Roviello F, Pedrazzani C, Marrelli D, et al.: Super-extended, (D3) lymphadenectomy in advanced gastric cancer. Eur J Surg Oncol 2010; 36: 439-446 (Epub 2010 Apr 13).
3. Isozaki H, Okajima K, Fujii K, et al.: Effectiveness of paraaortic lymph node dissection for advanced gastric cancer. Hepatogastroenterology 1999; 46: 549-554.
4. Kunisaki C, Shimada H, Yamaoka H, et al.: Indications for paraaortic lymph node dissection in gastric cancer patients with paraaortic lymph node involvement. Hepatogastroenterology 2000; 47: 586-589.
5. Tokunaga M, Ohyama S, Hiki N, et al.: Can superextended lymph node dissection be justified for gastric cancer with pathologically positive para-aortic lymph nodes? Ann Surg Oncol 2010; 17: 2031-2036.
6. Fujimura T, Nakamura K, Oyama K, et al.: Selective lymphadenectomy of para-aortic lymph nodes for advanced gastric cancer. Oncol Rep 2009; 22: 509-514.7.
7. Boku N, Yamamoto S, Fukuda H, et al.: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: A randomised phase 3 study. Lancet Oncol 2009; 10: 1063-1069.
8. Koizumi W, Narahara H, Hara T, et al.: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 2008; 9: 215-221.
9. Ajani JA, Fodor MB, Tjulandin SA, et al.: Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 2005; 23: 5660-5667.
10. Ross P, Nicolson M, Cunningham D, et al.: Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20: 1996-2004.
11. Fushida S, Fujimura T, Oyama K, et al.: Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases. Anticancer Drugs 2009; 20: 752-756.
12. Sato Y, Takayama T, Sagawa T, et al.: Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Cancer Chemother Pharmacol 2010; 66: 721-728.
13. Nakayama N, Koizumi W, Sasaki T, et al.: A multicenter, phase I dose-escalating study of docetaxel, cisplatin and S-1 for advanced gastric cancer (KDOG0601). Oncology 2008; 75: 1-7.
14. Cervantes A, Roselló S, Roda D, et al. The treatment of advanced gastric cancer: Current strategies and future perspectives. Ann Oncol 2008; 19: v103-v107.
15. Sakuramoto S, Sasako M, Yamaguchi T, et al.: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820.
16. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
17. Yoshikawa T, Sasako M, Yamamoto S, et al.: Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg 2009; 96: 1015-1022.
18. Ajani JA, Winter K, Okawara GS, et al.: Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): Quality of combined modality therapy and pathologic response. J Clin Oncol 2006; 24: 3953-3958.
19. Yonemura Y, Kinoshita K, Fujimura T, et al.: Correlation of the histological effects and survival after neoadjuvant chemotherapy on gastric cancer patients. Hepatogastroenterology 1996; 43: 1260-1272.
20. Sasako M, Sano T, Yamamoto S, et al.: D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008; 359: 453-462.
21. Fareed KR, Al-Attar A, Soomro IN, et al.: Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer 102: 1600-1607.
22. Fushida S, Fujimura T, Oyama K, et al.: Neoadjuvant chemotherapy combining docetaxel, cisplatin and S-1 in gastric cancer with para-aortic lymph node metastases: Report of five cases. Hepatogastroenterology 2010; 57: 1650-1654.
23. Japanese gastric cancer association.: Japanese gastric cancer A: Japanese classification of gastric carcinoma, 2nd English edition. Gastric cancer 1998; 1: 10-24.
24. Clavien PA, Barkun J, de Oliveira ML, et al.: The Clavien-Dindo classification of surgical complications: Five-year experience. Ann Surg 2009; 250: 187-196.
25. Nishi M, Omori Y, Miwa K,: editors: Japanese Research Society for Gastric Cancer. Response assessment of chemotherapy radiotherapy for gastric carcinoma part IV. In: Japanese classification gastric carcinoma. 1st edition. Tokyo: Kanehara; 1995.